Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Genomic diversity in low-risk disease: present and future

Nature Reviews Urology volume 15, pages 594–596 (2018)Cite this article

Subjects

New data have confirmed the genomic diversity of low-risk prostate cancer. Improved understanding of the heterogeneity of this disease has implications for disease management and has the potential to change treatment for patients in the future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Identification of the diverse genomic landscape of low-risk prostate cancer.

References

  1. Cooperberg, M. R. et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.05.014 (2018).

    Article  PubMed  Google Scholar 

  2. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017).

    Article  CAS  Google Scholar 

  3. Klein, E. A. et al. Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential. J. Urol. 197, 122–128 (2017).

    Article  CAS  Google Scholar 

  4. Spratt, D. E. et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J. Clin. Oncol. 36, 581–590 (2018).

    Article  Google Scholar 

  5. Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, Rochester, MN, USA

    Vidit Sharma & R. Jeffrey Karnes

Authors
  1. Vidit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Jeffrey Karnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Jeffrey Karnes.

Ethics declarations

Competing interests

R.J.K. declares research funding from GenomeDx and royalties related to Decipher. V.S. declares no competing interests.

Additional information

Related links

Decipher Genomic Resource Information Database: http://www.deciphergrid.com

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, V., Karnes, R.J. Genomic diversity in low-risk disease: present and future. Nat Rev Urol 15, 594–596 (2018). https://doi.org/10.1038/s41585-018-0073-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0073-2

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer